Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Aug;124(16):3290-3292.
doi: 10.1002/cncr.31574. Epub 2018 Jul 5.

Pragmatic approaches to address expansion cohort design

Suzanne E Dahlberg  1 , Robert J Gray  1
Affiliations
Editorial

Pragmatic approaches to address expansion cohort design

Suzanne E Dahlberg et al. Cancer. 2018 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Dahlberg reports a position on a steering committee for clinical trial sponsored by AstraZeneca. Dr. Gray has nothing to disclose.

Comment on

References

    1. Dahlberg SE, Shapiro GI, Clark JW, Johnson BE. Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience. J Natl Cancer Inst. 2014 Jun 24;106(7):dju163. doi: 10.1093/jnci/dju163. Print 2014 Jul. - DOI - PubMed
    1. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14):1038–1042. - PubMed
    1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–1037. - PubMed
    1. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500. - PubMed
    1. Lynch TJ, Bell DW, Sordella R. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139. - PubMed

LinkOut - more resources